Mar 8-11 2021



Maximising the Clinical Therapeutic Window of Antibody-drug Conjugates


Now in its 11th year, World ADC Europe prides itself in being the industry-leading conference to help forward thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates.

Since the last World ADC London in March of 2020, we have seen huge progress within the ADC field with the approval of Trodelvy from Immunomedics, Blenrep from GSK – and now with ADC Therapeutics submitting their BLA in September of 2020, could this be the next approved ADC?

Join fellow experts virtually across 140+ active organisations as they unite at this industry focussed digital conference to learn the latest ADC intelligence, foster new connections and develop business relationships with partners.


This year, you can be part of Europe's longest standing and most comprehensive ADC conference from the comfort and safety of your workplace and continue to power the development of your ADC pipeline in 2021.


Inovotion Head Of Business Development Philippe Fornies will be attending.
Please feel free to contact him to discuss your future projects.
We provide personalized solutions for each of our clients, our solutions are fast, sensitive, reliable, and affordable.
We are looking forward to working with you !


Abstract of the poster which you can download below :


Since its introduction, xenografts on the chicken embryo's ChorioAllantoic Membrane (CAM) has proven extremely valuable for in vivo studies of tumor development, angiogenesis and malignant cell dissemination. The CAM's ability to efficiently grow inoculated xenogenic tumor cells greatly simplify the analysis of human tumor cell metastasis. Here we demonstrate that our in ovo model is useful for rapidly testing and comparing efficacy of Antibody Drug Conjugates (ADCs) not only on tumors, but also on metastasic invasion.
Embryonated chicken eggs N87 gastric carcinoma cells grafted on the CAM were treated with different ADCs consisting of trastuzumab (Herceptin®) and 5 different payloads.
Tumor efficacy was measured via the reduction in tumor weight compared to the negative control group (treated with only the vehicle). Thus, we observed a dose-dependent effect for all ADCs and were able to rank them according to their efficacy from 0% (Ctrl ADC) to 60% reduction in tumor weight for the most effective.
In addition to efficacy on primary tumors, we also determined the effect of ADCs on the dissemination of cancer cells. Thus, two ADCs with the same efficacy on tumors showed two radically different effects on metastasis: one showed no particular efficacy while the second reduced metastasis to 20% of those observed in the negative control group.



* Fields required

By checking this box, I accept the privacy policy of this site.Learn more

All our news

All our webinars